RET+ NSCLC
Specialty Channel

Featured Article
True or false: Selpercatinib in combination with crizotinib targets MET-amplified resistance found in RET+ non-small cell lung cancer.
Researchers combining selpercatinib with crizotinib were able to target MET-amplified resistance among patients with RET+ NSCLC treated with selpercatinib alone.
Selpercatinib was shown to be effective, with manageable safety, in patients with RET+ medullary thyroid cancer in a phase 1/2 trial.
Which of the following applications were recently granted accelerated approval by the FDA for adult and pediatric advanced or metastatic RET-altered thyroid cancer requiring systemic therapy?
The FDA has approved pralsetinib for the treatment of adult and pediatric patients with RET-mutated thyroid cancer.
True or False: In a phase 2 clinical trial, pembrolizumab plus docetaxel did not improve overall response rates and progression-free survival in pretreated patients with NSCLC.
In a phase 2 study of pretreated patients with NSCLC, pembrolizumab plus docetaxel substantially improved overall response rates and PFS.

News

Researchers combining selpercatinib with crizotinib were able to target MET-amplified resistance among patients with RET+ NSCLC treated with selpercatinib alone.
Selpercatinib was shown to be effective, with manageable safety, in patients with RET+ medullary thyroid cancer in a phase 1/2 trial.
The FDA has approved pralsetinib for the treatment of adult and pediatric patients with RET-mutated thyroid cancer.
In a phase 2 study of pretreated patients with NSCLC, pembrolizumab plus docetaxel substantially improved overall response rates and PFS.

Interactive Features

True or false: Selpercatinib in combination with crizotinib targets MET-amplified resistance found in RET+ non-small cell lung cancer.
Which of the following applications were recently granted accelerated approval by the FDA for adult and pediatric advanced or metastatic RET-altered thyroid cancer requiring systemic therapy?
True or False: In a phase 2 clinical trial, pembrolizumab plus docetaxel did not improve overall response rates and progression-free survival in pretreated patients with NSCLC.
Stay in the know.
OncNet Newsletter